Gillis v. QRX Pharma Ltd.

OPINION & ORDER

PAUL A. ENGELMAYER, District Judge:

In this putative class action under the federal securities laws, lead plaintiffs Marsha Gillis, Carl Bayney, and Daniel Rehmsmeyer (collectively, “plaintiffs”) claim that the Australian pharmaceutical company QRx Pharma Ltd. (“QRX” or the “Company”) and its former CEO John Ho-laday made false and misleading statements about MoxDuo IR (“MoxDuo”), QRX’s leading drug candidate, while it was under review by the U.S. Food and Drug Administration (“FDA”).

Plaintiffs bring this lawsuit on behalf of all persons who purchased QRX American Depository…